Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bexarotene Combined With Ultra-Low Dose TSEB Radiotherapy in CTCL
NCT05296304Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bexarotene in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Incidence of radiation dermatitis grade 3+. Started Mar 2022; status: recruiting.
02
Drugs
bexarotene
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT05296304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296304.